The Deepening Debate Over Vaccines And Antimicrobial Resistance Involves IP 12/04/2017 by Tatum Anderson for Intellectual Property Watch 1 Comment With the looming threat of antimicrobial resistance (AMR), there is growing pressure to use vaccines because they obviate the need to prescribe antibiotics in the first place.
Hiring Freeze At USPTO Concerns Industry Groups 11/04/2017 by Intellectual Property Watch 3 Comments Members of the United States innovator business community have delivered a letter to President Trump requesting that the US Patent and Trademark Office be exempt from the federal hiring freeze announced in January.
UNCTAD Electronic Commerce Week: Exploring How All Can Benefit 06/04/2017 by Catherine Saez, Intellectual Property Watch 1 Comment Later this month, the third edition of the United Nations Conference on Trade and Development week dedicated to electronic commerce will take place. With a value estimated at US$22 trillion globally, e-commerce is booming for business, but mostly still escaping developing countries.
Advisory Group Supports Industry Demand For Audit Of WHO Pandemic Flu Framework 05/04/2017 by Catherine Saez, Intellectual Property Watch 2 Comments The World Health Organization has been recommended to provide details on its spending of funds provided to its pandemic influenza framework by the private sector.
Public-Private Coalition’s High-Profile Delinkage Policy For Emerging Vaccines 04/04/2017 by Tatum Anderson for Intellectual Property Watch 1 Comment It’s early February in Tchaourou district, Borgou in Benin, and a pregnant woman is admitted to hospital. Her premature baby is born by caesarean section but she dies a day later on February 12th. It turns out she had Lassa fever, a deadly viral haemorrhagic disease. But that’s only discovered after the baby is discharged from hospital and taken to northern Togo. The newborn also becomes ill and is taken to hospital for treatment.
Report Finds Wide Gap In Pharma Companies’ Profits And Spending On R&D 03/04/2017 by Intellectual Property Watch 2 Comments A new report from Public Citizen, the US-based consumer rights advocacy group, shows that the 20 largest pharmaceutical corporations are spending significantly less on research and development of new medicines than they are making in profits.
Report: Market Share Of Orphan Drugs Could Top 20 Percent Of Global Market By 2022 03/04/2017 by Intellectual Property Watch Leave a Comment A new industry report shows that the average prices for orphan drugs are increasing and are projected to comprise more than 20 percent of the patented pharmaceutical sales market by 2022.
France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment 31/03/2017 by Intellectual Property Watch 2 Comments The French Ministry of Social Affairs and Health announced today that the ministry has negotiated with pharmaceutical company Gilead to bring down the prices of hepatitis C medicines.
US Congress Considers Plan For Presidential Appointment Of Copyright Register 31/03/2017 by Dugie Standeford for Intellectual Property Watch 1 Comment Legislation authorising the president to appoint the Register of Copyright in the United States Copyright Office is working its way through Congress. The “Register of Copyrights Selection and Accountability Act” garnered strong bipartisan support in the House of Representatives Judiciary Committee as well as from the content community, but others fear it will politicise the […]
Funding Injection For New Antibiotics: The CARB-X Transatlantic Partnership 30/03/2017 by Kim Treanor for Intellectual Property Watch 1 Comment A partnership of government agencies and organisations in the United States and United Kingdom have announced an investment of up to US$48 million into the development of new antibiotics and products to fight antibiotic resistant bacteria, with the aim of having two new antibiotics in human trials in the next five years.